Drug intelligence / Profile preview

INB-01

Development stage: Unknown
Lead developer: IN8bio
Modality: Cell Therapies
Administration: Intravenous

Overview

INB-01 is an autologous gamma-delta T-cell therapy being developed for the treatment of hematologic malignancies, specifically targeting patients with high-risk leukemia following hematopoietic stem cell transplantation (HSCT). The therapy utilizes ex vivo expanded and activated gamma-delta T cells, which are a unique subset of T lymphocytes that possess innate-like properties, allowing them to recognize and kill tumor cells in a non-MHC-restricted manner. This mechanism reduces the risk of graft-versus-host disease (GvHD) while potentially enhancing the graft-versus-leukemia effect. Developed by IN8bio, INB-01 is designed to provide a safe and effective cellular immunotherapy option for patients who have limited treatment alternatives after undergoing bone marrow transplantation.

Beyond the preview

Go deeper on INB-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INB-01.

Explore the full profile